Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation

• Main Authors: Kyaw Zwar Myint (Author), Brinda Balasubramanian (Author), Simran Venkatraman (Author), Suchada Phimsen (Author), Supisara Sripramote (Author), Jeranan Jantra (Author), Chaiwat Choeiphuk (Author), Somkit Mingphruedhi (Author), Paramin Muangkaew (Author), Narongsak Rungsakulkij (Author), Pongsatorn Tangtawee (Author), Wikran Suragul (Author), Watoo Vassanasiri Farquharson (Author), Kanokpan Wongprasert (Author), Somchai Chutipongtanate (Author), Pimtip Sanvarinda (Author), Marisa Ponpuak (Author), Naravat Poungvarin (Author), Tavan Janvilisri (Author), Tuangporn Suthiphongchai (Author), Kiren Yacqub-Usman (Author), Anna M. Grabowska (Author), David O. Bates (Author), Rutaiwan Tohtong (Author)
• Format: Book
• Published: MDPI AG, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Cholangiocarcinoma (CCA) is a difficult-to-treat cancer, with limited therapeutic options and surgery being the only curative treatment. Standard chemotherapy involves gemcitabine-based therapies combined with cisplatin, oxaliplatin, capecitabine, or 5-FU with a dismal prognosis for most patients. R...